ReviewDrug safety2014
Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients.
Review in Drug safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience.Frontiers in oncology · 2021Pooled it
- EGFR Inhibitor-Induced Delayed Wound Healing Following PICC-port Implantation: Three Cases and a Literature Review.Clinical, cosmetic and investigational dermatology · 2026Article
- The Adverse Impact of Tyrosine Kinase Inhibitors on Wound Healing and Repair.International wound journal · 2025Review
- Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations.Current oncology (Toronto, Ont.) · 2025Review
- Impact of presurgical systemic therapy on perioperative outcomes of renal cell carcinoma with inferior vena cava tumor thrombus.International journal of clinical oncology · 2025Article
- Risk stratification of residual abscess after surgical treatment for gastroduodenal perforation.Annals of gastroenterological surgery · 2025Article
- Leukocytosis and thrombocytosis after splenectomy: expected finding, infection, or something else: a case report.Journal of medical case reports · 2024Article
- Paraspinal Desmoid Tumor in a Pediatric Patient with No Surgical History: A Case Report.Asian journal of neurosurgery · 2024Article
- Neoadjuvant systemic therapy for hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Article
- A case of markedly impaired wound repair with angiostatic pazopanib in a patient who had Mohs surgery for a basal cell carcinoma.SAGE open medical case reports · 2023Article
- Current and future outlook of loaded components in hydrogel composites for the treatment of chronic diabetic ulcers.Frontiers in bioengineering and biotechnology · 2023Review
- Proteomic Profiling of Saliva and Tears in Radiated Head and Neck Cancer Patients as Compared to Primary Sjögren's Syndrome Patients.International journal of molecular sciences · 2022Article
- Somatic Mosaicism of a PDGFRB Activating Variant in Aneurysms of the Intracranial, Coronary, Aortic, and Radial Artery Vascular Beds.Journal of the American Heart Association · 2022Article
- Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review.Cancers · 2021Review
- Article
- A Review of the Contribution of Mast Cells in Wound Healing: Involved Molecular and Cellular Mechanisms.Clinical reviews in allergy & immunology · 2020Review
- Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme.Respiratory research · 2020Review
- Mast Cells in Skin Scarring: A Review of Animal and Human Research.Frontiers in immunology · 2020Article
- Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib inThyroid : official journal of the American Thyroid Association · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small-molecule tyrosine kinase inhibitors (TKIs) represent a major advance in the treatment of certain forms of cancer. Unexpectedly, however, their use is associated with serious toxic effects on many vital organs and functions. Some of these effects, such as venous thromboembolism, haemorrhage, gastric perforation and a potential for impaired tissue healing, have direct implications for the safety of surgery in cancer patients. A number of currently approved TKIs are suspected or have been reported to impair wound healing but, understandably, there have been no formal pre- or post-approval clinical trials to evaluate the extent of the risk. Consequently, drug labels typically recommend discontinuation of the TKI concerned prior to elective surgery. In patients with gastric perforation, permanent discontinuation is advised. These recommendations, which are based on a precautionary principle, raise a dilemma, especially in patients with TKI-responsive tumours. This review focuses on the labelled potential of these novel antineoplastic agents to impair tissue repair and wound healing, and the evidence concerning the likely mechanisms involved. At present, because of the lack of formal clinical data, there are no evidence-based guidelines on the management of surgery in patients treated with TKIs. There is a need for a central registry of clinical outcomes following emergency surgery in cancer patients receiving TKIs and TKI-naïve matched controls. Analysis of outcomes data from such registries will assist in formulating guidelines on the management of elective surgery in TKI-treated patients. If TKIs are shown to significantly impair wound healing, patients receiving TKI therapy will require special monitoring and a collaborative approach between oncologists and surgeons for individualized reappraisal of the risk/benefit of the TKI treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.